Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
500 | 500 | 14,594,757 | 1,642 | Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an HLA-matched individual. Sequences are further selec... | 1. A method of identifying cancer antigens for preparing a cancer vaccine, comprising
a) obtaining a plurality of mutant sequences from the nucleic acid of cancer cells from a cancer patient, said mutant sequences coding for all or a portion of an expressed gene and wherein the mutant sequences each have a mutant posit... | Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an HLA-matched individual. Sequences are further selec... | 1,600 |
501 | 501 | 15,255,263 | 1,623 | A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles. | 1-24. (canceled) 25. A process for forming a gel comprising:
forming an oxidized cellulose solution; forming a precipitating composition; and contacting the oxidized cellulose solution and the precipitating composition at a treatment site thereby precipitating oxidized cellulose from the oxidized cellulose solution and... | A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles.1-24. (canceled) 25. A process for forming a gel comprising:
forming an oxidized cellulose solution; forming a precipitating composition; and cont... | 1,600 |
502 | 502 | 14,605,729 | 1,644 | A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell. | 1-43. (canceled) 44. A method of inducing apoptosis in a cancer cell expressing a C3a receptor (C3aR) and a C5a receptor (C5aR), the method comprising: administering amounts of a C3a antagonist and a C5a antagonist directly or locally to the cancer cell; wherein the amounts of the C3a antagonist and the C5a antagonist ... | A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.1-43. (canceled) 44. A method of ind... | 1,600 |
503 | 503 | 14,937,142 | 1,658 | The present invention relates to method for producing hypo-metallated redox-active metallothionein (MT) proteins, pharmaceutical compositions containing the proteins, and uses the pharmaceutical compositions for treatment of conditions originating from elevated intracellular oxidative stress and/or dis-balanced intrace... | 1. A method for producing a hypo-metallated redox-active metallothionein protein, the hypo-metallated redox-active metallothionein protein having 20 cysteine sulfhydryl groups and 7 binding pockets, 2 to 16 of the 20 cysteine sulfhydryl groups being free and reduced, and 1 to 6 of the 7 binding pockets being occupied b... | The present invention relates to method for producing hypo-metallated redox-active metallothionein (MT) proteins, pharmaceutical compositions containing the proteins, and uses the pharmaceutical compositions for treatment of conditions originating from elevated intracellular oxidative stress and/or dis-balanced intrace... | 1,600 |
504 | 504 | 13,808,163 | 1,656 | The present invention relates to methods of enhancing fermentation for the production of fermentation products. Specifically, the invention relates to enhancing fermentation in processes of producing ethanol from plant material using one or more fermenting organisms. | 1. A method of fermenting sugars derived from plant material in a fermentation medium using a fermenting organism, wherein one or more GH61 polypeptides are added to the fermentation medium. 2. A process of producing a fermentation product from lignocellulose-containing material, comprising the steps of:
(a) pre-treati... | The present invention relates to methods of enhancing fermentation for the production of fermentation products. Specifically, the invention relates to enhancing fermentation in processes of producing ethanol from plant material using one or more fermenting organisms.1. A method of fermenting sugars derived from plant m... | 1,600 |
505 | 505 | 15,131,586 | 1,658 | A method for treating a hyperglycemia and hyperglycemia-dependent side effects in a subject undergoing chemotherapy includes a step of identifying a subject undergoing chemotherapy and being administered a hyperglycemia-inducing agent. Short-term starvation or a fasting mimicking diet is administered for a first time p... | 1. A method for treating a hyperglycemia in a subject undergoing chemotherapy, the method comprising:
a) identifying a subject undergoing chemotherapy and having hyperglycemia and/or being administered a hyperglycemia-inducing agent; and b) administering short-term starvation (STS), a fasting mimicking diet (FMD) or in... | A method for treating a hyperglycemia and hyperglycemia-dependent side effects in a subject undergoing chemotherapy includes a step of identifying a subject undergoing chemotherapy and being administered a hyperglycemia-inducing agent. Short-term starvation or a fasting mimicking diet is administered for a first time p... | 1,600 |
506 | 506 | 15,175,848 | 1,644 | Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formu... | 1. An isolated chimeric or humanized antibody that specifically binds to human CD47, and comprises at least one CDR sequence as set forth in SEQ ID NO:3-8, SEQ ID NO:20-25; SEQ ID NO:28-33 or SEQ ID NO:61-66. | Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formu... | 1,600 |
507 | 507 | 15,135,677 | 1,619 | Described herein is a hair care composition having from about 0.2% to about 10% of one or more surfactant soluble active agents, from about 1% to about 10% of one or more viscosity reducing agents having a partition dispersion coefficient of from about 0.05 to about 2.0, from about 16% to about 40% of one or more anion... | 1) A hair care composition comprising:
a) from about 0.2% to about 10% of one or more surfactant soluble active agents, by weight of the hair care composition; b) from about 1% to about 10% of one or more viscosity reducing agents, by weight of the hair care composition, having a partition dispersion coefficient of fro... | Described herein is a hair care composition having from about 0.2% to about 10% of one or more surfactant soluble active agents, from about 1% to about 10% of one or more viscosity reducing agents having a partition dispersion coefficient of from about 0.05 to about 2.0, from about 16% to about 40% of one or more anion... | 1,600 |
508 | 508 | 14,849,203 | 1,637 | The invention provides methods for identifying modulators of ion channels without the use of recombinant cell lines over-expressing the ion channel proteins or the use of detection labels. | 1. A method of determining ion channel modulating properties of a test reagent comprising:
(a) applying cells to a surface of a colorimetric resonant reflectance optical biosensor; (b) substantially blocking the functional activity of one or more first types of ion channels, wherein the activity of one or more second t... | The invention provides methods for identifying modulators of ion channels without the use of recombinant cell lines over-expressing the ion channel proteins or the use of detection labels.1. A method of determining ion channel modulating properties of a test reagent comprising:
(a) applying cells to a surface of a colo... | 1,600 |
509 | 509 | 14,355,903 | 1,627 | The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule. | 1. A method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor of the Formula II
by administering the BRAF inhibitor of Formula II on an intermittent dosing schedule. 2. A method of claim 1 wherein the BRAF... | The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.1. A method of treating a prolifer... | 1,600 |
510 | 510 | 14,452,453 | 1,653 | A tissue system includes: a support material; and a vascular network comprising a plurality of channels disposed in the support material. A method includes printing a bioink in a support structure to form a network of vascular precursor materials; and converting the vascular precursor materials into a physiologically r... | 1. A tissue system, comprising:
a support material, and a vascular network comprising a plurality of channels disposed in the support material, wherein the vascular network is physiologically relevant. 2. The system as recited in claim 1, wherein the vascular network comprises a plurality of constituents selected from ... | A tissue system includes: a support material; and a vascular network comprising a plurality of channels disposed in the support material. A method includes printing a bioink in a support structure to form a network of vascular precursor materials; and converting the vascular precursor materials into a physiologically r... | 1,600 |
511 | 511 | 15,346,926 | 1,627 | The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of th... | 1-12. (canceled) 13. Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from said syndromes, said method comprising administering to said patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically accept... | The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of th... | 1,600 |
512 | 512 | 15,414,456 | 1,642 | Disclosed herein are panels related to the diagnosis or recognition of advanced adenoma and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments... | 1. A method of assessing colorectal health of an individual, comprising:
obtaining a circulating blood sample from said individual; detecting protein levels for each member of a list of proteins in sample, said list of proteins comprising DPPIV, CO9, TFRC, ORM1, MIF, PKM, SAA, and CEA; and obtaining age information and... | Disclosed herein are panels related to the diagnosis or recognition of advanced adenoma and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments... | 1,600 |
513 | 513 | 14,432,011 | 1,611 | The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising: -an aqueous phase, -particles comprising: *at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point ranging from 65° C. to 120° C., the hard wax(es) being present at a... | 1. An emulsion-type cosmetic composition, comprising:
an aqueous phase; particles comprising:
a hard wax having a melting point ranging from 65 to 120° C., the hard wax being present at a total content greater than or equal to 10% by weight relative to [[the]] a total weight of the composition, and
an aqueous dispersio... | The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising: -an aqueous phase, -particles comprising: *at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point ranging from 65° C. to 120° C., the hard wax(es) being present at a... | 1,600 |
514 | 514 | 14,762,043 | 1,613 | The present invention relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable support: a) at least one merocyanine compound of formula (1) or (2) and b) at least one oily phase and c) at least one C 1 -C 4 monoalkanol. The present invention also relates to a non-therapeutic cosm... | 1. Cosmetic or dermatological composition comprising, in a physiologically acceptable support:
a) at least one merocyanine compound corresponding to one of the following formulae (1) and (2) or one of the E/E- or E/Z-geometrical isomer forms thereof:
in which:
R1 and R2 are, independently of each other, hydr... | The present invention relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable support: a) at least one merocyanine compound of formula (1) or (2) and b) at least one oily phase and c) at least one C 1 -C 4 monoalkanol. The present invention also relates to a non-therapeutic cosm... | 1,600 |
515 | 515 | 14,356,109 | 1,653 | A high yield method for fermenting carbohydrate to ethanol and prevention and/or disruption of biofilms, comprising: a) mixing a fermentation feedstock with a fermentation broth containing yeast and/or an enzyme, b) treating said mixture by adding a composition to the fermentor containing: 10-90 wt. % of an aldehyde se... | 1. A high yield method of fermenting carbohydrate to ethanol in a fermentor, comprising:
a) mixing a fermentation feedstock with a fermentation broth containing yeast and/or an enzyme, b) treating said mixture by adding a composition to the fermentor containing:
10-90 wt. % of an aldehyde selected from the group consis... | A high yield method for fermenting carbohydrate to ethanol and prevention and/or disruption of biofilms, comprising: a) mixing a fermentation feedstock with a fermentation broth containing yeast and/or an enzyme, b) treating said mixture by adding a composition to the fermentor containing: 10-90 wt. % of an aldehyde se... | 1,600 |
516 | 516 | 14,397,060 | 1,644 | Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided. | 1. A method of identifying a chemotherapeutic agent, said method comprising performing a binding assay between CD19 and phosphatidylinositide 3-kinase (PI3K) in the presence of at least one test compound, wherein a decrease in the amount of CD19-PI3K binding in the presence of the test compound compared to the binding ... | Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.1. A method of identifying a chemotherapeutic agent, said method comprising performing a binding assay between CD19 and phosphatidylinositide 3-kinase (PI3K) in the presence of at least one test compound, wherein a decre... | 1,600 |
517 | 517 | 15,501,989 | 1,615 | A starting (raw) material, for cosmetics, comprising a core corona type microgel dispersion obtained by radical polymerization of a specific polyethylene oxide macromonomer, a specific hydrophobic monomer, and a specific cross-linking monomer under specific conditions. The purpose of the present invention is to provide... | 1.-8. (canceled) 9. A raw material, for cosmetics, comprising:
a core-corona type microgel dispersion; wherein said core-corona type microgel dispersion is obtained by a radical polymerization of:
(A) a polyethylene oxide macromonomer having chemical formula (1),
Wherein R1 is an alkyl group having 1 to 3 ... | A starting (raw) material, for cosmetics, comprising a core corona type microgel dispersion obtained by radical polymerization of a specific polyethylene oxide macromonomer, a specific hydrophobic monomer, and a specific cross-linking monomer under specific conditions. The purpose of the present invention is to provide... | 1,600 |
518 | 518 | 14,409,419 | 1,631 | Systems, methods and non-transitory computer readable media identify favored polymer conformations. One or more residues are identified and may be replaced in the polymer, or the original primary sequence of the polymer may be retained. The conformations of residues in a subset of residues in a region of the identified... | 1. A method of identifying one or more thermodynamically relevant polymer conformations for a polymer comprising a plurality of atoms, wherein the polymer comprises at least one contiguous segment of main chain, the method comprising:
at a computer system having one or more processors and memory storing one or more pro... | Systems, methods and non-transitory computer readable media identify favored polymer conformations. One or more residues are identified and may be replaced in the polymer, or the original primary sequence of the polymer may be retained. The conformations of residues in a subset of residues in a region of the identified... | 1,600 |
519 | 519 | 15,128,479 | 1,641 | A chemiluminescent detection system, as well as kits and microfluidics devices containing same, are disclosed. Methods of using the system, kits, and devices are also disclosed. The first, second, and third antibodies or binding fragments thereof may be provided in any form that allows these antibodies/binding fragment... | 1. A kit containing a chemiluminescent detection system for a specific analyte, the kit comprising:
(a) a first composition comprising a singlet-oxygen activatable chemiluminescent compound and a first antibody or binding fragment thereof associated therewith, wherein the first antibody or binding fragment thereof is a... | A chemiluminescent detection system, as well as kits and microfluidics devices containing same, are disclosed. Methods of using the system, kits, and devices are also disclosed. The first, second, and third antibodies or binding fragments thereof may be provided in any form that allows these antibodies/binding fragment... | 1,600 |
520 | 520 | 14,409,497 | 1,617 | The invention provides high water content dentifrice compositions comprising a silica abrasive and a component containing microcrystalline cellulose and carboxymethylcellulose, as well as methods of making and using the same. | 1. A dentifrice composition comprising by weight
a. 30-50% of water; b. 0.5% to 1.5% of a component for enhancing flavor delivery and rheological profile comprising:
b1. 80% to 90% of a microcrystalline cellulose; and
b2. 10% to 20% of carboxymethylcellulose or a salt thereof;
wherein the weight percentage of b1 and b2... | The invention provides high water content dentifrice compositions comprising a silica abrasive and a component containing microcrystalline cellulose and carboxymethylcellulose, as well as methods of making and using the same.1. A dentifrice composition comprising by weight
a. 30-50% of water; b. 0.5% to 1.5% of a compo... | 1,600 |
521 | 521 | 14,917,045 | 1,663 | This invention is intended to develop many DNA markers in plants of the genus Fragaria and to evaluate anthracnose resistance with high accuracy with the use of such many DNA markers. The markers associated with anthracnose resistance in plants of the genus Fragaria each comprise a continuous nucleic acid region sa... | 1. A marker associated with anthracnose resistance in plants of the genus Fragaria comprising a continuous nucleic acid region sandwiched between the nucleotide sequence as shown in SEQ ID NO: 1 and the nucleotide sequence as shown in SEQ ID NO: 10 in the chromosome of the plant of the genus Fragaria. 2. The marker ass... | This invention is intended to develop many DNA markers in plants of the genus Fragaria and to evaluate anthracnose resistance with high accuracy with the use of such many DNA markers. The markers associated with anthracnose resistance in plants of the genus Fragaria each comprise a continuous nucleic acid region sa... | 1,600 |
522 | 522 | 14,141,946 | 1,616 | Compositions for the transdermal delivery of NSAIDs in a flexible, finite form are described. The compositions comprise a polymer matrix that includes an NSAID and a polymer matrix comprising a blend of silicone and acrylic polymers. A flexible, occlusive backing material also is disclosed. | 1. A composition for the transdermal delivery of an NSAID in the form of a flexible finite system for topical application, comprising a polymer matrix comprising (i) a therapeutically effective amount of an NSAID; (ii) a silicone polymer; and (iii) an acrylic polymer or an acrylic block copolymer. 2. The composition of... | Compositions for the transdermal delivery of NSAIDs in a flexible, finite form are described. The compositions comprise a polymer matrix that includes an NSAID and a polymer matrix comprising a blend of silicone and acrylic polymers. A flexible, occlusive backing material also is disclosed.1. A composition for the tran... | 1,600 |
523 | 523 | 15,292,344 | 1,616 | Disclosed is a cosmetic or dermatological preparation which comprises glycyrrhetic acid and/or glycyrrhizin and further comprises at least one substance selected from UV filter substances, self-tanning agents and antioxidants. | 1. A cosmetic or dermatological preparation, wherein the preparation comprises at least one of glycyrrhetic acid and glycyrrhizin in an amount of at least 0.0001% by weight, based on a total weight of the preparation, and further comprises at least one substance which is selected from UV filter substances, self-tanning... | Disclosed is a cosmetic or dermatological preparation which comprises glycyrrhetic acid and/or glycyrrhizin and further comprises at least one substance selected from UV filter substances, self-tanning agents and antioxidants.1. A cosmetic or dermatological preparation, wherein the preparation comprises at least one of... | 1,600 |
524 | 524 | 14,416,438 | 1,612 | The invention relates to nail composition sets comprising at least one primer and at least one color coat, wherein the primer comprises water and at least one adhesive compound and preferably further comprises at least one water-soluble film forming agent and/or at least one plasticizer. | 1. A nail composition set comprising at least one primer and at least one color coat. 2. The nail composition set of claim 1, further comprising at least one basecoat and/or at least one topcoat. 3. The nail composition set of claim 1, wherein the color coat is a UV gel composition. 4. The nail composition set of claim... | The invention relates to nail composition sets comprising at least one primer and at least one color coat, wherein the primer comprises water and at least one adhesive compound and preferably further comprises at least one water-soluble film forming agent and/or at least one plasticizer.1. A nail composition set compri... | 1,600 |
525 | 525 | 15,015,458 | 1,633 | The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprise... | 1. A method for stimulating an immune response in a patient comprising selecting an elderly human patient exhibiting an age of at least 50 years and administering to the subject a composition comprising at least one mRNA encoding at least one antigen for the prophylaxis and/or treatment of a disease. 2. The method of c... | The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprise... | 1,600 |
526 | 526 | 14,819,342 | 1,625 | The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions comprising an anti-fungal... | 1. A method of treating or preventing a fungal infection in a subject, the method comprising:
(i) adding to water contained within a foot bath a compounded composition comprising fluconazole and LoxaSperse™ excipient base powder; (ii) agitating the water using an agitator, thereby distributing the compounded compositio... | The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions comprising an anti-fungal... | 1,600 |
527 | 527 | 15,154,499 | 1,631 | Methods, system, and kits are provided for sample identification, and, more specifically, for designing, and/or making, and/or using sample discriminating codes or barcodes for identifying sample nucleic acids or other biomolecules or polymers. For example, a plurality of flowspace codewords may be generated, the codew... | 1. A method for designing barcode sequences corresponding to flowspace codewords, comprising:
generating a plurality of flowspace codewords, the codewords comprising a string of characters; determining a location for at least one padding character within the flowspace codewords; inserting the padding character into the... | Methods, system, and kits are provided for sample identification, and, more specifically, for designing, and/or making, and/or using sample discriminating codes or barcodes for identifying sample nucleic acids or other biomolecules or polymers. For example, a plurality of flowspace codewords may be generated, the codew... | 1,600 |
528 | 528 | 15,447,019 | 1,633 | The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins. | 1.-77. (canceled) 78. A light-activated protein comprising:
a) a core polypeptide comprising an amino acid sequence at least 80% identical to the sequence shown in SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:4; b) an endoplasmic reticulum (ER) export signal; and c) a membrane trafficking signal. 79. The light-a... | The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.1.-77. (canceled) 78. A... | 1,600 |
529 | 529 | 15,597,676 | 1,612 | Disclosed herein are oral care compositions comprising hemp seed oil and caprylyl glycol. In certain embodiments, the oral care composition optionally further comprises one or more ingredients selected from hyaluronic acid and aloe vera. Methods of making and using the compositions are also provided. | 1. A mouthrinse comprising:
hemp seed oil; caprylyl glycol; and an orally acceptable base. 2. The mouthrinse of claim 1, wherein said composition has a moisture retention capacity of at least 4.8, as measured in an n vitro moisture retention capacity assay. 3. The mouthrinse of claim 2, wherein said hemp seed oil is pr... | Disclosed herein are oral care compositions comprising hemp seed oil and caprylyl glycol. In certain embodiments, the oral care composition optionally further comprises one or more ingredients selected from hyaluronic acid and aloe vera. Methods of making and using the compositions are also provided.1. A mouthrinse com... | 1,600 |
530 | 530 | 16,211,281 | 1,649 | Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal ... | 1. A composition comprising:
psilocybin, psilocin, baeocystin, norbaeocystin, or salts thereof, psilocybin mushrooms or extracts thereof, or combinations thereof; and niacin. 2. The composition of claim 1, wherein the composition further comprises Bacopa species (Bacopa monnieri), Gotu kola (Centella asiatica), Gingko ... | Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal ... | 1,600 |
531 | 531 | 12,758,315 | 1,645 | A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of... | 1. A composition comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. 2. The composition of claim 1, wherein said antigenic component is an N. meningitidis antigenic protein. 3. The composition of claim 2, wherein said outer membran... | A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of... | 1,600 |
532 | 532 | 12,675,614 | 1,634 | The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem ... | 1. A method of predicting a sleep parameter of an individual, the method comprising:
determining the individual's genotype at the PER3 variable number tandem repeat (VNTR) locus; and in the case that the individual's PER3 VNTR genotype is 5/5, predicting that the sleep parameter of the individual is indicative of bette... | The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem ... | 1,600 |
533 | 533 | 14,548,690 | 1,631 | Devices and methods for detecting heart failure (HF) events or identifying patient at elevated risk of developing future HF events, such as events indicative of HF decompensation status, are described. The devices and methods can detect an HF event or predict HF risk using signal transfigurations on different portions ... | 1. A system, comprising:
a physiologic signal analyzer circuit, including:
a physiologic signal receiver circuit configured to receive one or more physiologic signals; and
a signal trend generator configured to calculate a signal feature from the one or more physiologic signals and to generate a signal trend of the sig... | Devices and methods for detecting heart failure (HF) events or identifying patient at elevated risk of developing future HF events, such as events indicative of HF decompensation status, are described. The devices and methods can detect an HF event or predict HF risk using signal transfigurations on different portions ... | 1,600 |
534 | 534 | 14,170,373 | 1,631 | A biological pathway is a series of actions that take place in an organism that lead to some resulting pathology or otherwise change the organism state. In the cell, these actions typically take place between molecules called proteins. Proteins within the cell interact in ways that are not fully understood, but evidenc... | 1. A method for discovering a pathway among a set of biological and/or chemical entities, comprising:
a) providing documents about each of the biological and/or chemical entities; b) creating a vector space representation of the documents based on words and/or phrases occurring in the documents; c) for each biological ... | A biological pathway is a series of actions that take place in an organism that lead to some resulting pathology or otherwise change the organism state. In the cell, these actions typically take place between molecules called proteins. Proteins within the cell interact in ways that are not fully understood, but evidenc... | 1,600 |
535 | 535 | 15,236,897 | 1,616 | A herbicide and a method for killing targets plants is disclosed. The herbicide includes first and second amino acids applied to the leaves of the plant. The first and second amino acids, when combined interfere with at least one biological process. | 1. A herbicide comprising:
one of a first amino acid and a first and a second amino acid, the first and second amino acids, combined interfere with at least one biologic process within one of dandelions, and Canadian thistle. 2. The herbicide according to claim 1 wherein the one of a first amino acid and a first and a ... | A herbicide and a method for killing targets plants is disclosed. The herbicide includes first and second amino acids applied to the leaves of the plant. The first and second amino acids, when combined interfere with at least one biological process.1. A herbicide comprising:
one of a first amino acid and a first and a ... | 1,600 |
536 | 536 | 14,007,577 | 1,628 | The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17β HSD3/HSD10 inhibitor... | 1. An inhibitor of 17β-HSD1. 2. The inhibitor of claim 1, wherein the inhibitor has the structure:
wherein R is —OH, halo, —NH2, alkyl, alkoxy, aralkyl, carboxy, —CH2-heterocyclyl, heterocyclyloyl, —C(O)N(R′)(R″) or —B(OH)2,
wherein R′ and R″ are independently or simultanesouly H or alkyl, or R′ and R″ are jo... | The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17β HSD3/HSD10 inhibitor... | 1,600 |
537 | 537 | 14,904,407 | 1,629 | The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in t... | 1. A method of treating melanoma comprising administering to a subject in need thereof a therapeutically effective amount of a CDK (cyclin dependent kinase) inhibitor selected from the compound of formula I or a pharmaceutically acceptable salt thereof;
wherein Ar is phenyl, which is substituted by 1 or 2 di... | The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in t... | 1,600 |
538 | 538 | 15,019,694 | 1,627 | A gel paste composition including (A) a crosslinking organopolysiloxane and (B) a liquid oil, the crosslinking organopolysiloxane (A) being obtained by reacting an organohydrogenpolysiloxane shown by the following general formula (I) with a polyoxyalkylene compound shown by the following general formula (II) in the pre... | 1. A gel paste composition comprising
(A) a crosslinking organopolysiloxane; and (B) a liquid oil,
the crosslinking organopolysiloxane (A) being obtained by reacting an organohydrogenpolysiloxane shown by the following general formula (I) with a polyoxyalkylene compound shown by the following general formula (II) in th... | A gel paste composition including (A) a crosslinking organopolysiloxane and (B) a liquid oil, the crosslinking organopolysiloxane (A) being obtained by reacting an organohydrogenpolysiloxane shown by the following general formula (I) with a polyoxyalkylene compound shown by the following general formula (II) in the pre... | 1,600 |
539 | 539 | 12,444,516 | 1,653 | The invention relates to a process for the production of biogas from biomass, in particular from lignocellulose-containing biomass. According to the invention bio gas is produced from lignocellulose-containing biomass in a process, wherein the cellulose and hemicellulose in the lignocellulose are made accessible for bi... | 1. Process for the production of biogas from a feed stream of lignocellulose-containing biomass comprising the steps of:
i) subjecting the biomass stream to a temperature of 150-250° C. at a pH of 3-7; and ii) subjecting the product of step i) to anaerobic digestion, thereby producing a stream of biogas. 2. Process acc... | The invention relates to a process for the production of biogas from biomass, in particular from lignocellulose-containing biomass. According to the invention bio gas is produced from lignocellulose-containing biomass in a process, wherein the cellulose and hemicellulose in the lignocellulose are made accessible for bi... | 1,600 |
540 | 540 | 14,346,262 | 1,699 | An apparatus for detecting antibodies in a patient sample includes at least one incubation channel for accommodating a patient strip and for incubating the patient strip with a patient sample, a conjugate and a substrate and a control mechanism for visual inspection of incubation quality. A separate calibration strip h... | 1-8. (canceled) 9. An apparatus for detecting antibodies in a patient sample, comprising:
at least one incubation channel (3) for accommodating a patient strip (1) and for incubating the patient strip (1) with a patient sample, a conjugate and a substrate; a control means for visual inspection of incubation quality; an... | An apparatus for detecting antibodies in a patient sample includes at least one incubation channel for accommodating a patient strip and for incubating the patient strip with a patient sample, a conjugate and a substrate and a control mechanism for visual inspection of incubation quality. A separate calibration strip h... | 1,600 |
541 | 541 | 15,317,831 | 1,619 | Disclosed herein is a hair care product is provided, which comprises an oil-in-water emulsion A and an oil-in-water emulsion C, wherein emulsion A has a pH-value from greater than 7.0 to 12.0 and contains: a1) at least one cationic surfactant A, and a2) at least one amino-functionalized silicone A; and emulsion C has a... | 1. A hair care product comprising:
an oil-in-water emulsion A, where emulsion A has a pH-value from greater than about 7.0 to about 12.0 and comprises:
a1) at least one cationic surfactant A, and
a2) at least one amino-functionalized silicone A; and
an oil-in-water emulsion C, wherein
emulsion C has a pH-value from a... | Disclosed herein is a hair care product is provided, which comprises an oil-in-water emulsion A and an oil-in-water emulsion C, wherein emulsion A has a pH-value from greater than 7.0 to 12.0 and contains: a1) at least one cationic surfactant A, and a2) at least one amino-functionalized silicone A; and emulsion C has a... | 1,600 |
542 | 542 | 14,382,624 | 1,653 | Provided is a pesticidal Flavobacterium strain and bioactive compositions and metabolites derived therefrom as well as their methods of use for controlling pests. | 1. An isolated strain of a Flavobacterium sp. that has the following characteristics:
(A) a 16S rRNA gene sequence comprising the forward sequence having at least 99% identity to the sequence set forth in SEQ ID NO:3 and a reverse sequence having at least 99% identity to the sequence set forth in SEQ ID NO:4 and a cons... | Provided is a pesticidal Flavobacterium strain and bioactive compositions and metabolites derived therefrom as well as their methods of use for controlling pests.1. An isolated strain of a Flavobacterium sp. that has the following characteristics:
(A) a 16S rRNA gene sequence comprising the forward sequence having at... | 1,600 |
543 | 543 | 14,775,621 | 1,627 | A drink product having pharmaceutical compositions as an active ingredients of at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditio... | 1. An aqueous liquid formulation comprising:
(a) water and (b) at least one phosphorylated member selected from the group consisting of phosphorylated myoinositol having from one to nine phosphate groups inclusive of pyrophosphate groups in which each pyrophosphate is counted as two of the one to nine phosphate groups ... | A drink product having pharmaceutical compositions as an active ingredients of at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditio... | 1,600 |
544 | 544 | 16,010,995 | 1,616 | An oleogel comprising a non-polar liquid and a powder containing triterpene is provided as an oleogel that may be used for healing wounds. | 1. A method for enhancing the rate of reepithelialization of a wound, comprising administering to the wound an oleogel comprising a triterpene fraction, wherein the triterpene fraction comprises betulin. 2. The method of claim 1, wherein the triterpene fraction comprises between 1 weight-percent and 20 weight-percent o... | An oleogel comprising a non-polar liquid and a powder containing triterpene is provided as an oleogel that may be used for healing wounds.1. A method for enhancing the rate of reepithelialization of a wound, comprising administering to the wound an oleogel comprising a triterpene fraction, wherein the triterpene fracti... | 1,600 |
545 | 545 | 14,396,249 | 1,652 | The dairy industry today faces a problem of providing an alternative to adding sweeteners to fermented milk products in order to achieve the desired sweet taste without the added calories. Furthermore, it would be highly advantageous to establish a method for reducing lactose in fermented milk products to a level which... | 1. A galactose-fermenting Streptococcus thermophilus strain, wherein the strain carries a mutation in the DNA sequence of the glcK gene encoding a glucokinase protein, wherein the mutation inactivates the glucokinase protein or has a negative effect on expression of the gene. 2. The Streptococcus thermophilus strain ac... | The dairy industry today faces a problem of providing an alternative to adding sweeteners to fermented milk products in order to achieve the desired sweet taste without the added calories. Furthermore, it would be highly advantageous to establish a method for reducing lactose in fermented milk products to a level which... | 1,600 |
546 | 546 | 12,963,272 | 1,637 | Reagents and methods for analysis of DNA hydroxymethylation are provided. Methods comprise modification of hydroxymethylated cytosine residues with a bulky moiety to protect hydroxymethylated positions from cleavage with a DNA endonuclease. For example, methods may comprise contacting DNA with a glucosyltransferase to ... | 1. A method for detecting DNA hydroxymethylation in a DNA sample comprising:
(i) contacting a DNA sample comprising a glycosylated hydroxymethylcytosine with a DNA endonuclease to cleave the DNA; and (ii) detecting at least a first DNA sequence from a sample not cleaved by the DNA endonuclease to determine the presence... | Reagents and methods for analysis of DNA hydroxymethylation are provided. Methods comprise modification of hydroxymethylated cytosine residues with a bulky moiety to protect hydroxymethylated positions from cleavage with a DNA endonuclease. For example, methods may comprise contacting DNA with a glucosyltransferase to ... | 1,600 |
547 | 547 | 14,081,917 | 1,642 | An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. | 1. A method of prevention or treatment of a cancer comprising administering an anti-c-Met or an antigen-binding fragment thereof to a subject in need of prevention or treatment of the cancer. 2. The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable... | An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.1. A method of prevention or treatment of a cancer comprising administering an anti-c-Met or an antigen-binding fragm... | 1,600 |
548 | 548 | 13,646,589 | 1,642 | An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. | 1. An anti c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of CDR-H1 having an amino acid sequence of SEQ ID NO: 4, CDR-H2 having an amino acid sequence of SEQ ID ... | An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.1. An anti c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one he... | 1,600 |
549 | 549 | 14,910,846 | 1,616 | Spray drift reductants for agrochemical formulations and methods for reducing spray drift in agrochemical formulations are disclosed. An agrochemical formulation may comprise at least one spray drift reductant comprising a fatty acid ester of a C 3 to C 8 polyol, or an oligomer thereof having from 2 to 5 repeat units... | 1. A sprayable agrochemical formulation comprising;
i) at least one spray drift reductant comprising a fatty ester of a C3 to C8 polyol, or an oligomer thereof having from 2 to 5 repeat units; ii) at least one agrochemical active and/or nutrient; and iii) optionally a clathrate compound. 2. The formulation according to... | Spray drift reductants for agrochemical formulations and methods for reducing spray drift in agrochemical formulations are disclosed. An agrochemical formulation may comprise at least one spray drift reductant comprising a fatty acid ester of a C 3 to C 8 polyol, or an oligomer thereof having from 2 to 5 repeat units... | 1,600 |
550 | 550 | 15,491,924 | 1,615 | In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, fo... | 1. A method for maintaining ketosis in an individual, the method comprising:
orally administering a composition comprising approximately 0.5 g to approximately 10 g of R-beta-hydroxybutyrate; wherein administration induces or maintains ketosis in an individual. 2. The method of claim 1 wherein the amount of the composi... | In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, fo... | 1,600 |
551 | 551 | 14,701,779 | 1,644 | The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that spe... | 1. A method of treating a patient with an inflammatory or autoimmune disorder, said method comprising administering to said patient a pharmaceutical composition comprising an inhibitor of an NKG2D receptor, and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein said inhibitor is a monoclonal antib... | The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that spe... | 1,600 |
552 | 552 | 15,199,108 | 1,618 | The present invention relates to an improved synthesis of N-monofluoroalkyl tropanes using fluoroalkyl iodide. The invention also provides the use of such method to prepare the non-radioactive tropane intermediate FP-CIT, and its subsequent conversion to the 123 I-labelled radiopharmaceutical DaTSCAN™ ( 123 I-ioflupan... | 1. A method of preparation of a non-radioactive N-monofluoroalkyl tropane compound of Formula (IIIA)
which method comprises:
(iii) provision of an amine of Formula (III):
and
(iii) alkylation of said amine with an alkylating agent of formula F—(CH2)mI, in the presence of a base in a suitable solve... | The present invention relates to an improved synthesis of N-monofluoroalkyl tropanes using fluoroalkyl iodide. The invention also provides the use of such method to prepare the non-radioactive tropane intermediate FP-CIT, and its subsequent conversion to the 123 I-labelled radiopharmaceutical DaTSCAN™ ( 123 I-ioflupan... | 1,600 |
553 | 553 | 14,310,201 | 1,618 | Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R 1 , L 1 , L 2 , G, M,... | 1. A cyclic peptide having the following structure (I):
or a salt, tautomer, prodrug or stereoisomer thereof, wherein:
L1 and L2 are each individually optionally substituted linker moieties, each linker moiety optionally comprising a linkage to a solid support, a linkage to a reporter moiety, a linkage to a p... | Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R 1 , L 1 , L 2 , G, M,... | 1,600 |
554 | 554 | 13,635,075 | 1,644 | The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like recepto... | 1. A method of generating antigen loaded, activated dendritic cells (DC) for use in immunotherapy, comprising:
loading at least one antigen into a DC; activating the DC with at least one TLR agonist; cryopreserving the DC; and thawing the DC; wherein the DC produces an effective amount of at least one cytokine to gener... | The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like recepto... | 1,600 |
555 | 555 | 15,475,519 | 1,619 | A personal care composition for cosmetic treatment of skin that provides an improved moisturization signal to a user and exhibits good feel properties. The composition includes a dimethicone fluid or a blend of dimethicone fluids with a viscosity of greater than 1000 centistokes (cSt). The dimethicone fluid(s) are conf... | 1. A personal care composition, comprising:
a) about 5% to about 30%, by weight of the composition, of a blend of at least two dimethicone fluids, wherein the blend of dimethicone fluids exhibits a viscosity of greater than about 1000 centistokes (cSt) according to the Rheology Method; and b) a dermatologically accepta... | A personal care composition for cosmetic treatment of skin that provides an improved moisturization signal to a user and exhibits good feel properties. The composition includes a dimethicone fluid or a blend of dimethicone fluids with a viscosity of greater than 1000 centistokes (cSt). The dimethicone fluid(s) are conf... | 1,600 |
556 | 556 | 13,643,673 | 1,647 | A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as che... | 1. A method of alleviating a symptom of chemotherapy in a subject, the method comprising:
identifying a subject undergoing chemotherapy; administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject; and measuring the level of IGF-1 in the subject. 2. The method of claim 1 wh... | A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as che... | 1,600 |
557 | 557 | 14,858,181 | 1,611 | The sunscreen compositions of the present invention include a phase-stable, oil-in-water emulsion that includes a continuous water phase containing a superhydrophilic amphiphilic copolymer and a suspension of styrene/acrylate copolymer particles; and a discontinuous oil phase homogeneously dispersed in the continuous w... | 1. A sunscreen composition, comprising
a phase-stable, oil-in-water emulsion, comprising,
a continuous water phase comprising a superhydrophilic amphiphilic copolymer and a suspension of styrene/acrylate copolymer particles; and
a discontinuous oil phase homogeneously dispersed in the continuous water phase, the discon... | The sunscreen compositions of the present invention include a phase-stable, oil-in-water emulsion that includes a continuous water phase containing a superhydrophilic amphiphilic copolymer and a suspension of styrene/acrylate copolymer particles; and a discontinuous oil phase homogeneously dispersed in the continuous w... | 1,600 |
558 | 558 | 14,053,012 | 1,644 | Methods of assaying potency of a vaccine composition are provided. Said methods utilize a T cell receptor mimic that is reactive against a specific peptide/MHC complex. The potency of the vaccine is determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated ... | 1-20. (canceled) 21. A method of assaying the potency of a vaccine composition, the method comprising the steps of:
delivering a vaccine composition to at least one antigen presenting cell so that the antigen presenting cell displays a peptide/MHC complex having an epitope derived from the vaccine composition; contacti... | Methods of assaying potency of a vaccine composition are provided. Said methods utilize a T cell receptor mimic that is reactive against a specific peptide/MHC complex. The potency of the vaccine is determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated ... | 1,600 |
559 | 559 | 14,281,532 | 1,617 | Foamable sanitizing compositions are disclosed. The compositions contain alcohol, water, a foaming agent, and a foam strengthening agent. The foaming agent which may comprise a derivatized dimethicone has been found to cause the alcohol solution to foam even though alcohol has various defoaming properties. The foam str... | 1-23. (canceled) 24. A foamable composition comprising:
(a) a linear dimethicone copolyol ester, (b) at least one C1-4 alcohol in an amount of from about 30% to about 90% by weight, (c) water in an amount of at least 10% by weight, and (d) betaine. 25. The foamable composition as defined in claim 24, wherein the dimeth... | Foamable sanitizing compositions are disclosed. The compositions contain alcohol, water, a foaming agent, and a foam strengthening agent. The foaming agent which may comprise a derivatized dimethicone has been found to cause the alcohol solution to foam even though alcohol has various defoaming properties. The foam str... | 1,600 |
560 | 560 | 15,513,132 | 1,646 | The present invention relates to a therapeutic agent for pustular psoriasis or psoriatic erythroderma that is administered to a psoriasis patient that has been administered with an anti-TNF-alpha antibody, comprising an IL-17RA antagonist as an active ingredient; and to a therapeutic agent for psoriasis that is adminis... | 1. A therapeutic agent for pustular psoriasis or psoriatic erythroderma that is administered to a psoriasis patient that has been administered with an anti-TNF-alpha antibody, comprising an IL-17RA antagonist as an active ingredient. 2. The therapeutic agent according to claim 1, wherein the anti-TNF-alpha antibody is ... | The present invention relates to a therapeutic agent for pustular psoriasis or psoriatic erythroderma that is administered to a psoriasis patient that has been administered with an anti-TNF-alpha antibody, comprising an IL-17RA antagonist as an active ingredient; and to a therapeutic agent for psoriasis that is adminis... | 1,600 |
561 | 561 | 14,174,317 | 1,617 | Disclosed is a method of preparing a hair care composition comprising a step of controlling temperature when adding antidandruff agents. The method of the present invention provides reduced agglomeration of antidandruff agents selected from metal pyrithiones. | 1. A method of preparing a antidandruff compositions,
wherein the composition comprises: (a) a cationic surfactant system; (b) a high melting point fatty compound; (c) aqueous carrier; (d) an antidandruff agent selected from metal pyrithiones; and wherein the method comprises the steps of: (1) mixing the cationic surfa... | Disclosed is a method of preparing a hair care composition comprising a step of controlling temperature when adding antidandruff agents. The method of the present invention provides reduced agglomeration of antidandruff agents selected from metal pyrithiones.1. A method of preparing a antidandruff compositions,
wherein... | 1,600 |
562 | 562 | 15,618,792 | 1,663 | The present disclosure describes genetically-modified plants having enhanced tolerance to multiple abiotic stressors, such as extreme temperatures (heat or cold) and/or drought. Abiotic stress tolerance is enhanced by ectopic expression of a heterologous glutaredoxin. Abiotic stress tolerance (particularly drought) is ... | 1. A method of producing a genetically-modified plant having enhanced tolerance to an abiotic stressor as compared to a control plant, said method comprising:
transforming a plant with a heterologous, abiotic stress tolerance gene, wherein said gene encodes a glutaredoxin, thereby enhancing the tolerance of said geneti... | The present disclosure describes genetically-modified plants having enhanced tolerance to multiple abiotic stressors, such as extreme temperatures (heat or cold) and/or drought. Abiotic stress tolerance is enhanced by ectopic expression of a heterologous glutaredoxin. Abiotic stress tolerance (particularly drought) is ... | 1,600 |
563 | 563 | 15,305,114 | 1,627 | The object of the present invention is to provide a formulation with the effect of effectively suppressing or inhibiting amyloid fibril formation by the dissolution, elimination (discharge), etc. of amyloid fibril formation in vivo.
If an agent for suppressing or inhibiting an amyloid fibril formation comprising ... | 1-11. (canceled) 12. A method for suppressing or inhibiting an amyloid fibril formation comprising administering an agent for suppressing or inhibiting an amyloid fibril formation to a patient in need of suppressing or inhibiting an amyloid fibril formation, wherein the agent comprises tranilast or a pharmacologically ... | The object of the present invention is to provide a formulation with the effect of effectively suppressing or inhibiting amyloid fibril formation by the dissolution, elimination (discharge), etc. of amyloid fibril formation in vivo.
If an agent for suppressing or inhibiting an amyloid fibril formation comprising ... | 1,600 |
564 | 564 | 15,022,654 | 1,627 | Provided herein are methods of treating or preventing a neurodegenerative by administering fenofibrate or an analog thereof. | 1. A method of inducing PGC-1α expression in a neural cell comprising contacting a neural cell or population of neural cells with an effective amount of fenofibrate or an analog thereof. 2. The method of claim 1, wherein the contacting step is in vivo. 3. The method of claim 1 or 2, wherein the contacting step in vitro... | Provided herein are methods of treating or preventing a neurodegenerative by administering fenofibrate or an analog thereof.1. A method of inducing PGC-1α expression in a neural cell comprising contacting a neural cell or population of neural cells with an effective amount of fenofibrate or an analog thereof. 2. The me... | 1,600 |
565 | 565 | 15,698,846 | 1,613 | The present disclosure is directed to an enhanced biocide composition containing an isothiazolinone and a pyrithione. In particular, the composition contains an isothiazolinone, a pyrithione, a zinc compound, and an organic amine. According to the present disclosure, the combination of components employed within the co... | 1. A biocide composition comprising:
an isothiazolinone, a pyrithione, a zinc compound, and an organic amine. 2. The biocide composition of claim 1, wherein the isothiazolinone comprises 1,2-benzisothiazolin-3-one, N-butyl-1,2-benzisothiazolin-3-one, N-methyl-1,2-benzisothiazolin-3-one, 2-methyl-2H-isothiazol-3-one, 5-... | The present disclosure is directed to an enhanced biocide composition containing an isothiazolinone and a pyrithione. In particular, the composition contains an isothiazolinone, a pyrithione, a zinc compound, and an organic amine. According to the present disclosure, the combination of components employed within the co... | 1,600 |
566 | 566 | 15,394,485 | 1,662 | The present invention relates to novel gene sequences encoding insecticidal proteins produced by Bacillus thuringiensis strains. Particularly, new chimeric genes encoding a CryIC, CryIB or CryID protein are provided which are useful to protect plants from insect damage. Also included herein are plant cells or plants ... | 1. A chimeric gene comprising the following operably-linked sequences:
a) a coding region encoding a Cry1C protein; comprising a DNA sequence with at least 98% sequence identity to the DNA of any one of SEQ ID Nos. 1, 3, 4 or 6, wherein said Cry1C protein is a protein comprising the amino acid sequence from the amino a... | The present invention relates to novel gene sequences encoding insecticidal proteins produced by Bacillus thuringiensis strains. Particularly, new chimeric genes encoding a CryIC, CryIB or CryID protein are provided which are useful to protect plants from insect damage. Also included herein are plant cells or plants ... | 1,600 |
567 | 567 | 15,468,694 | 1,653 | Provided are processes for facilitating the removal of a biological stain is provided wherein a substrate or coating including a protease is capable of enzymatically degrading of one or more components of the biological stain to facilitate biological stain removal from the substrate or said coating. | 1. A method of facilitating the removal of a biological stain on a substrate or a coating comprising:
providing a substrate or a coating; associating a protease with said substrate or said coating such that said substrate or said coating is capable of enzymatically degrading a component of a biological stain. 2. The me... | Provided are processes for facilitating the removal of a biological stain is provided wherein a substrate or coating including a protease is capable of enzymatically degrading of one or more components of the biological stain to facilitate biological stain removal from the substrate or said coating.1. A method of facil... | 1,600 |
568 | 568 | 14,414,218 | 1,613 | Embodiments of various aspects described herein relates to compositions and methods for encapsulation and/or stabilization of oil, lipid, hydrophobic and/or lipophilic compounds in a silk-based material. The compositions described herein can be used in various applications, e.g., pharmaceutical, cosmetic, food, diagnos... | 1. A silk particle comprising at least two immiscible phases, a first immiscible phase comprising a silk-based material and a second immiscible phase comprising an active agent, wherein the first immiscible phase encapsulates the second immiscible phase and the second immiscible phase excludes a liposome. 2. The silk p... | Embodiments of various aspects described herein relates to compositions and methods for encapsulation and/or stabilization of oil, lipid, hydrophobic and/or lipophilic compounds in a silk-based material. The compositions described herein can be used in various applications, e.g., pharmaceutical, cosmetic, food, diagnos... | 1,600 |
569 | 569 | 15,064,792 | 1,641 | Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sectio... | 1. An antibody-signal-generating moiety conjugate comprising an antibody covalently linked to a signal-generating moiety through a heterobifunctional PEG linker. 2. The conjugate of claim 1, wherein a thiol-reactive group of the linker is covalently linked to the antibody and an amine-reactive group of the heterobifunc... | Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sectio... | 1,600 |
570 | 570 | 14,122,872 | 1,628 | The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of: a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of formula (III), wherein P 1 and P 2 are each independently a protecting group select... | 1. A process for the preparation of a compound of formula (I)
said process comprising the steps of
a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of formula (III), wherein P1 and P2 are each independently a protecting group selected from R2−Si—R3R4, or R... | The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of: a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of formula (III), wherein P 1 and P 2 are each independently a protecting group select... | 1,600 |
571 | 571 | 15,008,646 | 1,623 | The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering a 1-aminocyclohexane derivative such as memantine and an acetylcholinesterase inhibitor (AChEI) such as donepezil. | 1. A method for treating Alzheimer's disease in a subject in need thereof, comprising administration of a 1-aminocyclohexane derivative selected from memantine, and salts thereof, and an acetylcholinesterase inhibitor (AChEI) selected from donepezil, and salts thereof, wherein the combined treatment with the 1-aminocyc... | The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering a 1-aminocyclohexane derivative such as memantine and an acetylcholinesterase inhibitor (AChEI) such as donepezil.1. A method for treating Alzheimer's disease in a subject in need thereof, comprising a... | 1,600 |
572 | 572 | 15,129,811 | 1,646 | The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same. | 1. A method for treating nail or scalp psoriasis, comprising administering a composition comprising an antibody or fragment thereof to a patient wherein the antibody specifically binds to IL-17 Receptor A (IL-17RA) and has an antagonistic activity. 2. A method of according to claim 1, wherein the antibody or fragment t... | The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same.1. A method for treating nail or scalp psoriasis, comprising administering a compos... | 1,600 |
573 | 573 | 14,122,892 | 1,628 | The present invention relates to a process for the preparation of a compound of formula (I) comprising the steps of a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wherein P 1 is a protecting group selected from R 2 Si—R 3 R 4 or R 1 CO—, R 1 is a ... | 1. A process for the preparation of a compound of formula (I)
comprising the steps of
a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wherein P1 is a protecting group selected from R2—Si—R3R4 or R1CO—, R1 is a group selected from C1-6alkyl ... | The present invention relates to a process for the preparation of a compound of formula (I) comprising the steps of a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wherein P 1 is a protecting group selected from R 2 Si—R 3 R 4 or R 1 CO—, R 1 is a ... | 1,600 |
574 | 574 | 15,869,438 | 1,641 | The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the conce... | 1-8. (canceled) 9. A method of treating heart failure in a patient in need thereof, comprising the steps of:
a) obtaining a biological sample from said patient; b) measuring the concentration of IGFBP2 in the sample obtained in step a); c) determining the severity of the heart failure depending on the concentration of ... | The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the conce... | 1,600 |
575 | 575 | 15,520,756 | 1,628 | The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of se... | 1. A method for treating viral infection, the method comprising the step of administering to the subject an effective amount of at least one compound having a structure selected from:
or a pharmaceutically acceptable salt thereof, thereby treating the subject for viral infection. 2. The meth... | The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of se... | 1,600 |
576 | 576 | 15,599,420 | 1,646 | Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis an... | 1. A method of increasing serum transferrin saturation in a subject, the method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds mature bone morphogenetic protein-6 (BMP-6) or fragments thereof. 2. The method of claim 1... | Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis an... | 1,600 |
577 | 577 | 15,054,358 | 1,654 | An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularl... | 1. A method of prophylactically or therapeutically treating a disease, disorder or condition in a human in need thereof comprising
administering to the human a fixed dosage apolipoprotein formulation in order to prophylactically or therapeutically treat the disease, disorder, or condition in the human, wherein the dise... | An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularl... | 1,600 |
578 | 578 | 13,962,241 | 1,651 | Embodiments of the invention encompass the ex vivo production of cartilage from chondrocytes differentiated from fibroblasts or stem cells. In particular embodiments, fibroblasts are subjected to conditions to produce chondrocytes in the form of cartilage tissue, for example cartilage having a desired shape. In at leas... | 1. A method of generating cartilage ex vivo, comprising the step of subjecting fibroblasts or stem cells to conditions to differentiate said fibroblasts or stem cells into chondrocytes ex vivo to produce cartilage. 2. The method of claim 1, wherein the cartilage is configured in the form of a desired shape. 3. The meth... | Embodiments of the invention encompass the ex vivo production of cartilage from chondrocytes differentiated from fibroblasts or stem cells. In particular embodiments, fibroblasts are subjected to conditions to produce chondrocytes in the form of cartilage tissue, for example cartilage having a desired shape. In at leas... | 1,600 |
579 | 579 | 15,405,968 | 1,628 | The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15α, 16α, 17β-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within... | 1. A method of emergency contraception in a mammalian female comprising the administration of an emergency contraceptive comprising tetrahydroxylated estrogen represented by the general formula (I):
wherein R1, R2, R3, R4 independently are a hydrogen atom; a hydroxyl group, an alkoxy group with 1-5 carbon ato... | The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15α, 16α, 17β-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within... | 1,600 |
580 | 580 | 15,414,722 | 1,642 | The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer. | 1-3. (canceled) 4. A method for treating a patient, wherein the patient has colon cancer, a colorectal cancer or a rectal cancer, comprising administering a therapeutically effective amount of aflibercept or ziv-aflibercept to the patient, wherein a level of a biomarker selected from the group consisting of VCAM-1, ICA... | The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.1-3. (canceled) 4. A method for treating a patient, wherein the patient has colon cancer, a colorectal cancer... | 1,600 |
581 | 581 | 14,704,254 | 1,641 | Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis. | 1. A method for managing a an animal colony, the method comprising:
(a) collecting blood samples from a plurality of members of the colony on a plurality of collection cards; (b) allowing the blood samples to dry on the collection cards; (c) transporting the collection cards to a laboratory as a single unit; (d) extrac... | Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.1. A method for managing a an animal colony, t... | 1,600 |
582 | 582 | 11,658,220 | 1,643 | Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for ... | 1. A method for detecting bladder cancer in a subject, comprising:
detecting the accumulation of a urinary bladder tumor marker (“UBTM”) family member in the urine, said accumulation in said subject greater than about 1.2 times the accumulation of said UBTM in urine from a group of normal subjects not having malignant ... | Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for ... | 1,600 |
583 | 583 | 15,476,849 | 1,635 | Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a po... | 1. A molecule of Formula (I):
A-X-B-Y-C Formula I
wherein,
A is an antibody or its binding fragments thereof;
B is a polynucleotide;
C is a polymer;
X is a bond or first non-polymeric linker; and
Y is a bond or second linker;
wherein the polynucleotide comprises at least one 2′ modified nucleotide, at least one m... | Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a po... | 1,600 |
584 | 584 | 14,590,538 | 1,618 | Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2′, 4′, and 11′,as well as uses for the compounds for imaging, and the like. | 1. A method of imaging a T Cell comprising:
administering to the subject a compound having formula 3; and imaging the subject, wherein detecting the presence of the compound corresponds to the presence of the T cell, wheiren formula 3 is represented by the following structure,
wherein Ist is an isotope, whe... | Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2′, 4′, and 11′,as well as uses for the compounds for imaging, and the like.1. A method of imaging a T Cell comprising:
administering... | 1,600 |
585 | 585 | 15,976,346 | 1,617 | A method for the treatment of facial Rosacea and skin erythema using pyrithione zinc aqueous solution of given concentration strength as the sole active ingredient in a topically applied fluid composition in which the pyrithione zinc aqueous solution comprises about 20% to about 30% of the fluid composition by volume, ... | 1. A method of treating erythema resulting from facial Rosacea in a subject comprising the step of topically administering to the face of said subject a fluid composition consisting of an inactive moisturizer carrier and a single active ingredient, wherein the single active ingredient consists of a pyrithione zinc aque... | A method for the treatment of facial Rosacea and skin erythema using pyrithione zinc aqueous solution of given concentration strength as the sole active ingredient in a topically applied fluid composition in which the pyrithione zinc aqueous solution comprises about 20% to about 30% of the fluid composition by volume, ... | 1,600 |
586 | 586 | 15,107,133 | 1,651 | The invention provides a method for identifying methicillin resistant Staphylococcus aureus (MRSA) in a bacterial sample comprising the steps: classifying bacteria in the sample as Staphylococcus aureus (SA) and determining the presence or absence of the phenol soluble modulin peptide or a variant thereof wherein t... | 1. A method for identifying methicillin resistant Staphylococcus aureus (MRSA) in a bacterial sample comprising the steps:
classifying bacteria in the sample as Staphylococcus aureus (SA), directly depositing whole bacteria cells on a MALDI time of flight (MALDI-TOF) mass spectrometer target plate without prior extract... | The invention provides a method for identifying methicillin resistant Staphylococcus aureus (MRSA) in a bacterial sample comprising the steps: classifying bacteria in the sample as Staphylococcus aureus (SA) and determining the presence or absence of the phenol soluble modulin peptide or a variant thereof wherein t... | 1,600 |
587 | 587 | 15,291,504 | 1,613 | Process for thickening a composition, through the use of a direct emulsion in water, which is alkali-swellable, of a polymer of the ASE or HASE type, which is both rich in acrylic acid and which has a certain quantity of AMPS. The use of such emulsions simultaneously allows there to be no obligation to use surfactants ... | 1. A method for thickening a formulation, the method comprising:
contacting the formulation with a direct aqueous emulsion of a polymer followed by regulating a pH of the formulation to a value between 5 and 7, thereby forming a thickened formulation, wherein the emulsion is free from surfactants and organic solvents o... | Process for thickening a composition, through the use of a direct emulsion in water, which is alkali-swellable, of a polymer of the ASE or HASE type, which is both rich in acrylic acid and which has a certain quantity of AMPS. The use of such emulsions simultaneously allows there to be no obligation to use surfactants ... | 1,600 |
588 | 588 | 13,630,577 | 1,632 | The present invention relates to the field of degradation with hyperthermophilic organisms, and in particular to the use of hyperthermophilic degradation to produce heat and energy rich components including hydrogen and ethanol from a biomass. In some embodiments, a biomass is fermented in the presence of hyperthermoph... | 1. A process comprising:
providing a biomass that contains a pathogen and a population of at least one genus of a hyperthermophilic organism; culturing said population of at least one genus of a hyperthermophilic organism under anaerobic conditions on said biomass at a temperature of 80° C. or higher; maintaining said ... | The present invention relates to the field of degradation with hyperthermophilic organisms, and in particular to the use of hyperthermophilic degradation to produce heat and energy rich components including hydrogen and ethanol from a biomass. In some embodiments, a biomass is fermented in the presence of hyperthermoph... | 1,600 |
589 | 589 | 15,307,948 | 1,651 | In the present invention, for test cells which are either stem cells whose state of differentiation is unknown or cells obtained from stem cells by differentiation induction, an LC-MS or GC-MS analysis is performed on culture supernatants collected from a culture dish of the test cells and a culture dish of control cel... | 1. A cell differentiation state assessment method, comprising:
assessing a state of differentiation of test cells based on an amount of a specified substance in a culture supernatant of the test cells, the test cells being stem cells whose state of differentiation is unknown or cells obtained from stem cells by differe... | In the present invention, for test cells which are either stem cells whose state of differentiation is unknown or cells obtained from stem cells by differentiation induction, an LC-MS or GC-MS analysis is performed on culture supernatants collected from a culture dish of the test cells and a culture dish of control cel... | 1,600 |
590 | 590 | 15,094,113 | 1,618 | Described herein is the androgen receptor modulator of formula (I)
in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment w... | 1. A method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient comprising orally administerin... | Described herein is the androgen receptor modulator of formula (I)
in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment w... | 1,600 |
591 | 591 | 14,987,256 | 1,699 | Provided in this disclosure are methods and compositions that find use in a variety of multiplex cellular/tissue section analyses. In certain aspects, a tissue section (or planar cellular slide) is stained with a combination of “visible” labels and “invisible” labels for specific targets of interest. The visible labels... | 1. A method for multiplex analysis of a tissue section, comprising:
staining a tissue section for a first target and a second target, wherein the first target is stained with a detectable label in the visible spectrum and the second target is stained with a detectable label in the non-visible spectrum; detecting the fi... | Provided in this disclosure are methods and compositions that find use in a variety of multiplex cellular/tissue section analyses. In certain aspects, a tissue section (or planar cellular slide) is stained with a combination of “visible” labels and “invisible” labels for specific targets of interest. The visible labels... | 1,600 |
592 | 592 | 15,590,598 | 1,634 | Methods of identifying potential skin moisturizing actives for the treatment of dry skin and method of formulating a moisturizing skin care composition using actives identified by the method. Moisturizing agents can be identified by comparing the transcriptional profile of a skin tissue sample contacted by a test agent... | 1. A screening method for identifying a cosmetic test agent as a skin moisturizing agent, the method comprising:
a. contacting a skin tissue sample with a cosmetic test agent; b. generating a transcriptional profile for the skin tissue sample, wherein the transcriptional profile comprises data related to the transcript... | Methods of identifying potential skin moisturizing actives for the treatment of dry skin and method of formulating a moisturizing skin care composition using actives identified by the method. Moisturizing agents can be identified by comparing the transcriptional profile of a skin tissue sample contacted by a test agent... | 1,600 |
593 | 593 | 15,300,984 | 1,628 | Embodiments of the disclosure include methods and compositions related to treatment of one or more medical conditions with one or more negative modulators of GABA A receptors. In specific embodiments, depression and/or suicidability is treated or ameliorated or prevented with one or more negative modulators of GABA A ... | 1. A method of treating or preventing or ameliorating at least one symptom of a medical condition in an individual, comprising the step of providing to the individual a therapeutically effective amount of one or more negative modulators of GABAA receptors, wherein the medical condition is selected from the group consis... | Embodiments of the disclosure include methods and compositions related to treatment of one or more medical conditions with one or more negative modulators of GABA A receptors. In specific embodiments, depression and/or suicidability is treated or ameliorated or prevented with one or more negative modulators of GABA A ... | 1,600 |
594 | 594 | 13,929,252 | 1,633 | The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue f... | 1. A method for treating tissue comprising:
selecting a tissue comprising adipocytes for implantation; contacting the tissue with a detergent at a concentration and time sufficient to remove non-viable materials from the tissue; and rinsing the tissue to remove the detergent. 2. The method according to claim 1, wherein... | The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue f... | 1,600 |
595 | 595 | 14,441,901 | 1,611 | The present invention relates to an effervescent tablet, which upon dissolution in water provides a solution useful as a mouth wash or oral rinse for the prevention or treatment of inflammatory processes of the soft tissues of the mouth, throat and oral cavity. | 1. An effervescent tablet comprising:
a) a pharmaceutically effective amount of one or more phosphate salts; b) a pharmaceutically effective amount of a calcium salt; c) one or more effervescing organic acid component; and d) one or more effervescing base component; wherein said tablet upon dissolution in water provide... | The present invention relates to an effervescent tablet, which upon dissolution in water provides a solution useful as a mouth wash or oral rinse for the prevention or treatment of inflammatory processes of the soft tissues of the mouth, throat and oral cavity.1. An effervescent tablet comprising:
a) a pharmaceutically... | 1,600 |
596 | 596 | 15,700,446 | 1,613 | Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dis... | 1. A medical device comprising an antimicrobial coating, wherein the coating comprises at least one water permeable polymer and uniformly dispersed particles therein of at least one antimicrobial agent, and wherein the particles and any agglomerations of the antimicrobial agent have an average size of no greater than 5... | Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dis... | 1,600 |
597 | 597 | 14,725,714 | 1,619 | According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen. | 1. A drug delivery system comprising a labeled pre-filled syringe containing a sterile aqueous solution of baclofen that is suitable for intrathecal delivery, wherein the sterile aqueous solution of baclofen was sterilized by heating at 121° C. for a F0 value of 7 minutes. 2. The drug delivery system of claim 1, wherei... | According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.1. A drug delivery system comprising a labeled pre-filled syring... | 1,600 |
598 | 598 | 14,233,546 | 1,631 | The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the ... | 1. A method comprising:
inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) (20) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, wherein the infer... | The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the ... | 1,600 |
599 | 599 | 14,150,488 | 1,611 | A method for sterilizing an antiseptic solution includes providing a container containing the antiseptic solution, the antiseptic solution having an initial purity, selecting a sterilization temperature from about 85° C. to about 135° C. and an sterilization time from about 1 minute to about 19 hours, heating the antis... | 1. The sterile antiseptic solution of claim 23, prepared by a method comprising the steps of:
providing a container containing a pre-sterilized antiseptic solution, the pre-sterilized antiseptic solution having an initial purity; selecting a sterilization temperature from about 85° C. to about 135° C. and a sterilizati... | A method for sterilizing an antiseptic solution includes providing a container containing the antiseptic solution, the antiseptic solution having an initial purity, selecting a sterilization temperature from about 85° C. to about 135° C. and an sterilization time from about 1 minute to about 19 hours, heating the antis... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.